U.S., Jan. 29 -- ClinicalTrials.gov registry received information related to the study (NCT06797024) titled 'JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders' on Jan. 19.
Brief Summary: his study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed/refractory neurologic immune disorders. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed/refractory neurologic immune disorders.
Study Start Date: Feb. 08
Study Type: INTERVENTIONAL
Condition:
Autoimmune Diseases of the Nervous System
Intervention:
DRUG: JY231 Injection
JY231 injection is administe...